Morgan Stanley Remains Bullish on Intuitive Surgical (ISRG)

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best medical stocks to buy now. Morgan Stanley analyst Patrick Wood maintained a Buy rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) on September 29 and set a price target of $650.00.

Intuitive Surgical, Inc. (ISRG): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential

The analyst based the optimistic rating on the company’s potential in the endoluminal robotics market, reasoning that the recent success of EndoQuest’s PARADIGM trial reflects a notable opportunity for Intuitive Surgical, Inc. (NASDAQ:ISRG). The PARADIGM trial demonstrated the feasibility of performing complex colorectal lesions using endoscopic submucosal dissection (ESD).

Wood noted that while the procedure is technically challenging, it offers improved clinical outcomes compared to the more common methods in practice in the United States, which is why its success could pave the way for a broader adoption of robotic-assisted surgeries.

Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems.

While we acknowledge the potential of ISRG to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ISRG and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.